Meloxicam Alkaline Solid Dispersion for Rapid Acute Pain Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, exhibits low solubility and high Tmax, limiting its effectiveness in treating acute pain, especially when administered under fasted conditions, and existing formulations often include cyclodextrin derivatives that pose stability concerns.
Innovation Solution
A novel pharmaceutical composition of meloxicam is developed by embedding it in alkaline surroundings with hydrophilic polymers and alkalizing agents, forming a solid dispersion to enhance solubility and absorption, avoiding cyclodextrin derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If meloxicam is administered in pure form, then the formulation is simple, but solubility is low and Tmax is high
Solution Approach 1:
The patent uses cyclodextrin derivatives to form inclusion complexes with meloxicam, creating a composite material system where the cyclodextrin host molecule encapsulates the meloxicam guest molecule. This composite structure improves solubility and absorption rate while maintaining formulation simplicity
Solution Approach 2:
The patent modifies the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrin derivatives, changing the solubility and dissolution characteristics without altering the chemical structure of meloxicam itself, thereby improving absorption rate
2Speed
If cyclodextrin derivatives are used to improve solubility, then absorption rate increases, but stability concerns arise
Solution Approach 1:
The patent introduces alkalizing agents as intermediary substances that create an alkaline environment to stabilize the cyclodextrin-meloxicam inclusion complex, preventing degradation and improving formulation stability while maintaining the absorption rate benefits
Solution Approach 2:
The patent creates an inert alkaline environment using alkalizing agents that protect the cyclodextrin derivative inclusion complex from degradation, effectively shielding the formulation from stability issues while preserving the improved absorption characteristics
3Speed
If meloxicam is administered under fasted conditions, then absorption is faster, but solubility remains low
Solution Approach 1:
The patent creates a model system using cyclodextrin derivatives that replicates and enhances the solubility properties needed for fasted state absorption, effectively copying and improving upon the natural dissolution behavior to achieve both high solubility and fast absorption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves rapid drug release, increased absorption, and reduced Tmax, providing higher Cmax and AUC, effectively treating acute pain without stability issues.
Implementation Method 1
embedding it in alkaline surroundings with hydrophilic polymers and alkalizing agents, forming a solid dispersion to enhance solubility and absorption
Implementation Method 2
Meloxicam has pKa values of 1.1 and 4.2. In particular, the solubility of meloxicam varies depending upon pH and solvent polarity due to interconversion between ionization states
Data Source
AI summary
The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.